Fosun Pharma subsidiary gets trial approval, parent company sees leadership changes

Shanghai Fosun Pharmaceutical Group's controlled subsidiary, Shanghai Henlius Biotech, has received approval from China's National Medical Products Administration to commence Ib/II phase clinical trials for its HLX43 and HLX07 drug combination. This regimen is intended for treating advanced/metastatic solid tumors. HLX43 is an antibody-drug conjugate targeting PD-L1, while HLX07 is an innovative biological drug targeting EGFR. As of August 2025, the accumulated R&D investment for this treatment regimen stands at approximately RMB 150,000.

Concurrently, the company announced significant leadership changes. Mr. Wu Yifang resigned as a non-executive director, effective September 30, 2025, due to personal work changes. The board has nominated Mr. Liu Yi, currently the chief executive and president, as a candidate for executive director, pending shareholder approval. Mr. Liu Yi also holds positions in several controlled subsidiaries, including as executive director and chairman of Sisram Medical Ltd, and non-executive director of Shanghai Henlius Biotech.

Additionally, Mr. Zhou Xudong resigned as senior vice president, effective September 30, 2025, due to personal development reasons. The company expressed gratitude to both Mr. Wu and Mr. Zhou for their contributions.